GoldenGolden
Advanced Search

Crescendo Biologics

Crescendo Biologics is an antibody Fragments.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

May 2018
Crescendo Biologics raises a $70,000,000 series B round from Andera Partners and Quan Capital.
April 30, 2018
Crescendo Biologics raises a $70,000,000 series B round.
April 2014
Crescendo Biologics raises a $19,500,000 series A round from EMBL Ventures.
January 20, 2010
Crescendo Biologics raises a $7,300,000 series A round from Avlar BioVentures.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 20, 2021
BioSpace
First clinical trial from Crescendo's proprietary pipeline of novel, targeted T cell enhancing Humabody® therapeutics; initial clinical data expected in 2022
BioSpace
May 10, 2021
BioSpace
Crescendo Biologics Ltd, a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, announces the appointment of Dr Michael Booth as Chief Financial Officer.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.